Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 3/20 | 0.54 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.54 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.52 |
| ▸ | MCHR1 | Q99705 | 8/20 | 0.48 |
| ▸ | EGFR | P00533 | 4/20 | 0.46 |
| ▸ | MCHR2 | Q969V1 | 3/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | MET | P08581 | 1/20 | 0.42 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.40 |
| ▸ | AURKA | O14965 | 1/20 | 0.40 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.40 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.40 |
| ▸ | GSK3A | P49840 | 1/20 | 0.40 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.40 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.40 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.40 |
| ▸ | TAOK1 | Q7L7X3 | 1/20 | 0.40 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.40 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL521061 | 0.89 | HDAC3 (0.47) | HDAC3HDAC2HDAC1MCHR1EGFR | |
| SCHEMBL538977 | 0.89 | MCHR1 (0.53) | MCHR1MCHR2 | |
| SCHEMBL6069601 | 0.87 | MCHR1 (0.52) | MCHR1MCHR2 | |
| SCHEMBL16931323 | 0.86 | HDAC3 (0.52) | HDAC3HDAC2HDAC1MCHR1MCHR2 | |
| SCHEMBL110445 | 0.83 | EGFR (0.56) | HDAC3HDAC2HDAC1MCHR1EGFR | |
| SCHEMBL2961954 | 0.83 | HDAC3 (0.52) | HDAC3HDAC2HDAC1MCHR1EGFR | |
| SCHEMBL14534661 | 0.83 | MCHR1 (0.51) | HDAC3HDAC2HDAC1MCHR1EGFR | |
| SCHEMBL29804080 | 0.83 | EGFR (0.56) | HDAC3HDAC2HDAC1MCHR1EGFR | |
| SCHEMBL20859441 | 0.81 | HDAC3 (0.50) | HDAC3HDAC2HDAC1MCHR1EGFR | |
| SCHEMBL14594169 | 0.81 | MCHR1 (0.49) | HDAC3HDAC2HDAC1MCHR1EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023178928-A1 | 2-AMINO-4-INDOLYL PYRIMIDINE COMPOUNDS, PREPARATION METHOD THEREFOR AND USES THEREOF | 中国药科大学 | 2023-09-28 | — | — | WO | disclosed |
| US-9777020-B2 | Furo-3-carboxamide derivatives and methods of use | ABBVIE INC. (US) | 2017-10-03 | — | — | US | disclosed |
| EP-3097095-A1 | FURO-3-CARBOXAMIDE DERIVATIVES AND METHODS OF USE | AbbVie Inc. (US) | 2016-11-30 | — | — | EP | disclosed |
| US-9249125-B2 | Pyrazole derivatives as p38 MAP inhibitors | RESPIVERT LIMITED (GB) | 2016-02-02 | — | — | US | disclosed |
| US-9249125-B2 | Pyrazole derivatives as p38 MAP inhibitors | RESPIVERT LIMITED (GB) | 2016-02-02 | — | — | US | disclosed |
| US-9249125-B2 | Pyrazole derivatives as p38 MAP inhibitors | RESPIVERT LIMITED (GB) | 2016-02-02 | — | — | US | disclosed |
| US-20150210720-A1 | FURO-3-CARBOXAMIDE DERIVATIVES AND METHODS OF USE | ABBVIE INC. | 2015-07-30 | — | — | US | disclosed |
| WO-2015112754-A1 | FURO-3-CARBOXAMIDE DERIVATIVES AND METHODS OF USE | ABBVIE INC. (US) | 2015-07-30 | — | — | WO | disclosed |
| US-20150203475-A1 | PYRAZOLE DERIVATIVES AS P38 MAP INHIBITORS | TOPIVERT PHARMA LIMITED (GB) | 2015-07-23 | — | — | US | disclosed |
| US-20150203475-A1 | PYRAZOLE DERIVATIVES AS P38 MAP INHIBITORS | TOPIVERT PHARMA LIMITED (GB) | 2015-07-23 | — | — | US | disclosed |
| US-20150203475-A1 | PYRAZOLE DERIVATIVES AS P38 MAP INHIBITORS | TOPIVERT PHARMA LIMITED (GB) | 2015-07-23 | — | — | US | disclosed |
| EP-2376491-B1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | CEPHALON INC (US) | 2015-03-04 | — | — | EP | disclosed |
| WO-2014033448-A1 | PYRAZOLE DERIVATIVES AS P38 MAP INHIBITORS | RESPIVERT LIMTED (GB) | 2014-03-06 | — | — | WO | disclosed |
| US-8471005-B2 | Pyrrolotriazines as ALK and JAK2 inhibitors | CEPHALON, INC. (US) | 2013-06-25 | — | — | US | disclosed |
| US-20120028919-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | CEPHALON, INC. (US) | 2012-02-02 | — | — | US | disclosed |
| EP-2376491-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | Cephalon, Inc. (US) | 2011-10-19 | — | — | EP | disclosed |
| WO-2010071885-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | CEPHALON, INC. (US) | 2010-06-24 | — | — | WO | disclosed |
| US-7071182-B2 | Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor | ABBOTT LABORATORIES (US) | 2006-07-04 | — | — | US | disclosed |
| US-20050277638-A1 | Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor | ABBVIE INC. | 2005-12-15 | — | — | US | disclosed |
| US-20050137243-A1 | Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor | ABBOTT LABORATORIES | 2005-06-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150203475-A1 | PYRAZOLE DERIVATIVES AS P38 MAP INHIBITORS | SYK, FYN, MAPK1 | HDAC3 1870/4885HDAC2 805/4885HDAC1 995/4885 |
| US-20050137243-A1 | Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor | MCHR1, MCHR2, MC1R | HDAC3 3197/4885HDAC2 4093/4885HDAC1 4164/4885 |
| US-20050277638-A1 | Antagonists of melanin concentrating hormone effects on the melanin concentrating hormone receptor | MCHR1, MCHR2, MC1R | HDAC3 3197/4885HDAC2 4093/4885HDAC1 4164/4885 |
| US-20150210720-A1 | FURO-3-CARBOXAMIDE DERIVATIVES AND METHODS OF USE | NTRK2, MUSK, NTRK3 | HDAC3 131/4885HDAC2 560/4885HDAC1 172/4885 |
| US-20120028919-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | JAK2, ALK, ABL1 | HDAC3 841/4885HDAC2 1272/4885HDAC1 811/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.